44 CHAPTER 2 Extended Data Table 1. Available drugs and matching rules A list of the participating pharmaceutical companies, and the drugs that were available for this study. To be eligible for a given treatment, a patient needed to meet the description for the treatment that is marked with a + in this table (exclusion criteria are marked with −). Supplier Drug Indications Available Amgen Panitumumab + BRAF-KRAS-NRAS wild type tumors September 2016 - Patients eligible for on-label panitumumab and BRAF-KRAS-NRAS mutated tumors AstraZeneca Olaparib + ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, PP2R2A, RAD51B/C/D, RAD54L inactivating mutations September 2016 - Patients eligible for on-label olaparib or for the MEDIOLA, POLO, PROFOUND, REVIVAL or SUBITO trial. Bayer Regorafenib + BRAF, CSF1(R), FLT1/4, KDR, KIT, PDGFRβ, RAF1, RET activating mutations, amplifications, fusion or overexpression September 2016 - Patients eligible for on-label regorafenib Boehringer Ingelheim Afatinib + ERBB4 activating mutations or NRG1 activating mutations or fusions in non-small cell lung cancer September 2017 - All tumor types and profiles not fulfilling the subscription above Bristol-Myers Squibb Nivolumab + High mutational load or micro-satellite instable tumors, with MLH1, MSH2/6 or PMS2 mutations or non-expression September 2016 - Patients eligible for on-label nivolumab Eisai Lenvatinib + FGFR1/2/3/4 activating mutations, amplifications or fusions October 2017 - Patients eligible for on-label lenvatinib Merck Sharp & Dohme Pembrolizumab + High mutational load tumors September 2017 - Patients eligible for on-label pembrolizumab and multiple myeloma Novartis Dabrafenib + BRAF V600D/E/K/R activating mutations September 2016 - Patients eligible for on-label dabrafenib or for the ROAR trial, and tumors with MAP2K1/2 or NRAS mutations Nilotinib + + ABL1, KIT, PDGFRα, PDGFRβ activating mutations September 2016
RkJQdWJsaXNoZXIy MTk4NDMw